[go: up one dir, main page]

PL2807165T3 - Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych - Google Patents

Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Info

Publication number
PL2807165T3
PL2807165T3 PL13740815T PL13740815T PL2807165T3 PL 2807165 T3 PL2807165 T3 PL 2807165T3 PL 13740815 T PL13740815 T PL 13740815T PL 13740815 T PL13740815 T PL 13740815T PL 2807165 T3 PL2807165 T3 PL 2807165T3
Authority
PL
Poland
Prior art keywords
pyrimido
expansion
stem cells
hematopoietic stem
indole derivatives
Prior art date
Application number
PL13740815T
Other languages
English (en)
Inventor
Guy Sauvageau
Yves Gareau
Réjean RUEL
Stéphane GINGRAS
Iman FARES
Original Assignee
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2807165(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de Montréal filed Critical Université de Montréal
Publication of PL2807165T3 publication Critical patent/PL2807165T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13740815T 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych PL2807165T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27
EP13740815.9A EP2807165B1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
PCT/CA2013/050052 WO2013110198A1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Publications (1)

Publication Number Publication Date
PL2807165T3 true PL2807165T3 (pl) 2019-09-30

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13740815T PL2807165T3 (pl) 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Country Status (25)

Country Link
US (3) US9409906B2 (pl)
EP (1) EP2807165B1 (pl)
JP (1) JP6250556B2 (pl)
KR (1) KR102098122B1 (pl)
CN (1) CN104144931B (pl)
AU (1) AU2013212457B2 (pl)
BR (1) BR112014018524B1 (pl)
CA (1) CA2862140C (pl)
CY (1) CY1121799T1 (pl)
DK (1) DK2807165T3 (pl)
ES (1) ES2733946T3 (pl)
HK (1) HK1203945A1 (pl)
HR (1) HRP20191189T1 (pl)
HU (1) HUE044070T4 (pl)
IL (1) IL233587B (pl)
LT (1) LT2807165T (pl)
NZ (1) NZ627188A (pl)
PL (1) PL2807165T3 (pl)
PT (1) PT2807165T (pl)
RS (1) RS59002B1 (pl)
SG (1) SG11201404241SA (pl)
SI (1) SI2807165T1 (pl)
SM (1) SMT201900360T1 (pl)
TR (1) TR201909582T4 (pl)
WO (1) WO2013110198A1 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404241SA (en) 2012-01-27 2014-08-28 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CA2903463A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
CA2848575C (en) 2013-05-17 2021-01-26 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
WO2015131005A1 (en) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
EP3134409B1 (en) * 2014-04-22 2020-02-12 Université de Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
JP6795493B2 (ja) * 2014-09-18 2020-12-02 ウニヴェルシテ ド モントリオール ヒト造血細胞へのウイルス遺伝子導入を増強させるための化合物および方法
JP2018502115A (ja) * 2014-12-31 2018-01-25 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
WO2016118780A1 (en) * 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
AU2016273439B2 (en) 2015-06-05 2020-11-05 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
US20180346877A1 (en) * 2015-10-15 2018-12-06 Celularity, Inc. Natural killer cells and ilc3 cells and uses thereof
IL260257B2 (en) * 2015-12-28 2024-05-01 Novartis Ag Preparations and methods for the treatment of hemoglobinopathies
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN109843304A (zh) * 2016-05-07 2019-06-04 细胞结构公司 使用自然杀伤细胞治疗急性髓性白血病和多发性骨髓瘤的方法
AU2017325511B2 (en) * 2016-08-18 2021-12-09 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
US20190203230A1 (en) 2016-09-28 2019-07-04 Novartis Ag Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
BR112020006256A2 (pt) 2017-09-29 2020-10-20 Intellia Therapeutics, Inc. método in vitro de administração de mrna usando nanopartículas de lipídio
US11696928B2 (en) * 2017-11-03 2023-07-11 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
AU2019205262A1 (en) * 2018-01-03 2020-07-23 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2019161494A1 (en) * 2018-02-20 2019-08-29 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
PE20211655A1 (es) * 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN115176005A (zh) 2019-12-18 2022-10-11 诺华股份有限公司 用于治疗血红蛋白病的组合物和方法
CA3164153A1 (en) * 2019-12-18 2021-06-24 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
TW202137978A (zh) 2019-12-26 2021-10-16 日商大日本住友製藥股份有限公司 造血幹細胞之培養方法
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
AU2021297353A1 (en) * 2020-06-25 2023-02-02 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
WO2022020210A1 (en) 2020-07-18 2022-01-27 Ossium Health, Inc. Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion
AU2021360590A1 (en) 2020-10-14 2023-06-15 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health Inc CELLULAR THERAPY PROCESSES
WO2022230793A1 (ja) * 2021-04-26 2022-11-03 住友ファーマ株式会社 オキセピン誘導体
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
CA2130937A1 (en) 1992-04-03 1993-10-14 Gordon L. Bundy Pharmaceutically active bicyclic-heterocyclic amines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE69619114T2 (de) * 1995-07-06 2002-10-02 Novartis Ag, Basel Pyrolopyrimidine und verfahren zu ihrer herstellung
WO1998042708A2 (en) * 1997-01-08 1998-10-01 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
ES2257090T3 (es) 1998-11-17 2006-07-16 Smithkline Beecham Corporation Poliamidas ciclicas para tratar trombocitopenia.
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
EP1189609A4 (en) 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
EP1213965B1 (en) 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
WO2001039773A1 (en) 1999-12-06 2001-06-07 Smithkline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CA2436288A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002309703A1 (en) * 2001-05-09 2002-11-18 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
EP1556059A4 (en) 2002-06-06 2010-06-30 Smithkline Beecham MIMETICS OF THROMBOPOIETINE
AU2003297925A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
US7795024B2 (en) 2003-05-02 2010-09-14 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
KR20080020602A (ko) * 2005-04-28 2008-03-05 수퍼젠, 인크. 단백질 키나아제 저해제
JP5132554B2 (ja) 2005-07-14 2013-01-30 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｐｏ模倣剤としてのヘテロ四環化合物
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
CN101282929A (zh) 2005-08-15 2008-10-08 Irm责任有限公司 用作tpo模拟物的化合物和组合物
AU2007259739B2 (en) 2006-06-14 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Agents for promoting the growth of hematopoietic stem cells
JP2008050355A (ja) 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
AU2012229997B2 (en) 2011-03-15 2016-04-14 Lawrence Livermore National Security, Llc Tricyclic gyrase inhibitors
SG11201404241SA (en) 2012-01-27 2014-08-28 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
US20170334904A1 (en) 2017-11-23
KR20140121454A (ko) 2014-10-15
US10336747B2 (en) 2019-07-02
JP6250556B2 (ja) 2017-12-20
TR201909582T4 (tr) 2019-07-22
CN104144931B (zh) 2018-04-10
AU2013212457A1 (en) 2014-09-18
EP2807165A4 (en) 2015-08-26
SG11201404241SA (en) 2014-08-28
WO2013110198A1 (en) 2013-08-01
NZ627188A (en) 2015-12-24
US20160222017A1 (en) 2016-08-04
HRP20191189T1 (hr) 2019-10-04
DK2807165T3 (da) 2019-07-15
JP2015504902A (ja) 2015-02-16
SMT201900360T1 (it) 2019-07-11
CN104144931A (zh) 2014-11-12
US20150011543A1 (en) 2015-01-08
PT2807165T (pt) 2019-07-12
BR112014018524A2 (pt) 2021-06-08
BR112014018524A8 (pt) 2017-07-11
HUE044070T4 (hu) 2019-12-30
BR112014018524B1 (pt) 2023-03-28
SI2807165T1 (sl) 2019-08-30
HK1203945A1 (en) 2015-11-06
RS59002B1 (sr) 2019-08-30
EP2807165B1 (en) 2019-05-15
CA2862140A1 (en) 2013-08-01
ES2733946T3 (es) 2019-12-03
KR102098122B1 (ko) 2020-04-07
AU2013212457B2 (en) 2017-02-16
IL233587B (en) 2019-11-28
US9409906B2 (en) 2016-08-09
LT2807165T (lt) 2019-07-25
CA2862140C (en) 2020-04-21
CY1121799T1 (el) 2020-07-31
EP2807165A1 (en) 2014-12-03
IL233587A0 (en) 2014-08-31
HUE044070T2 (hu) 2019-09-30

Similar Documents

Publication Publication Date Title
IL233587A0 (en) The history of pyrimido [5,4-b]indole and their use in the expansion of stem cells for the production of hematopoietic stem cells
HK1202581A1 (en) Mesenchymal stem cells conditioned medium and methods of generating and using the same
PH12013500226A1 (en) 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
ZA201503828B (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CO6791616A2 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a
IL219424A0 (en) IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
ZA201506182B (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
EP2970885A4 (en) Expansion of adult stem cells in vitro
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
PT2989105T (pt) Compostos de pirazino[1,2-a]indole, sua preparação e utilização em medicamentos
ZA201508613B (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
AU2012904719A0 (en) Stem cell line and use thereof